Qihan Biotech

company

About

Qihan Biotech is a gene-editing organ transplantation technology developer.

  • 251 - 500

Details

Last Funding Type
Series A
Last Funding Money Raised
$7.80M
Industries
Biotechnology,Clinical Trials,Health Care,Medical,Medical Device
Founded date
Jan 1, 2017
Number Of Employee
251 - 500
Operating Status
Active

Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$100.30M
Qihan Biotech has raised a total of $100.30M in funding over 2 rounds. Their latest funding was raised on Mar 29, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 29, 2021 Series A $67M 1 Lilly Asia Ventures Detail
Sep 22, 2019 Series A $25.50M 1 Detail
Jul 23, 2018 Series A $7.80M 1 Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Qihan Biotech has made 1 investments. Their most recent investment was on Aug 19, 2019, when ResortPass raised $9M.
Date Company Name
Round Money Raised Industry Lead Investor
Aug 19, 2019 ResortPass
Series A $9M Hospitality

Investors

Number of Lead Investors
Number of Investors
1
3
Qihan Biotech is funded by 3 investors. Lilly Asia Ventures and Xinyi Biology are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Yes Series A
Xinyi Biology Series A
ARCH Venture Partners Series A